{"filing":{"accession_number":"0001730430-26-000029","cik":"0001730430","ticker":"KNSA","company_name":"Kiniksa Pharmaceuticals International, plc","form":"8-K","filing_date":"2026-05-29","report_date":null,"primary_document":"knsa-20260529x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1730430/000173043026000029/knsa-20260529x8k.htm"},"events":[{"id":8262,"run_id":7251,"accession_number":"0001730430-26-000029","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear Item 5.07 disclosure of shareholder voting results from Kiniksa's Annual Meeting of Shareholders held on May 29, 2026. The filing presents detailed vote tallies for eight proposals including director re-elections (Proposal 1), auditor appointments (Proposals 2-4), financial statements (Proposal 5), and executive compensation approvals (Proposals 6-8). All proposals passed. This is material as it documents the outcome of the company's annual shareholder meeting and confirms governance decisions including board composition and auditor retention.","company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","filing_date":"2026-05-29","form":"8-K","submitted_at":null,"items":[{"id":2898,"accession_number":"0001730430-26-000029","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear Item 5.07 disclosure of shareholder voting results from Kiniksa's Annual Meeting of Shareholders held on May 29, 2026. The filing presents detailed vote tallies for eight proposals including director re-elections (Proposal 1), auditor appointments (Proposals 2-4), financial statements (Proposal 5), and executive compensation approvals (Proposals 6-8). All proposals passed. This is material as it documents the outcome of the company's annual shareholder meeting and confirms governance decisions including board composition and auditor retention.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:40:32.278268+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2898,"accession_number":"0001730430-26-000029","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear Item 5.07 disclosure of shareholder voting results from Kiniksa's Annual Meeting of Shareholders held on May 29, 2026. The filing presents detailed vote tallies for eight proposals including director re-elections (Proposal 1), auditor appointments (Proposals 2-4), financial statements (Proposal 5), and executive compensation approvals (Proposals 6-8). All proposals passed. This is material as it documents the outcome of the company's annual shareholder meeting and confirms governance decisions including board composition and auditor retention.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:40:32.278268+00:00","company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","filing_date":"2026-05-29"}]}